Biomarkers of Major Depressive Disorder: Knowing is Half the Battle

키워드

참고문헌 (118)

1. Strawbridge R, "Biomarkers for depression : recent insights, current challenges and future prospects", Focus, 16, pp.194~209 (2018)
2. Aydemir O, "The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients : a preliminary study", Prog Neuropsychopharmacol Biol Psychiatry, 29, pp.261~265 (2005)
3. Mercier A, "Evidence of prescription of antidepressants for non-psychiatric conditions in primary care : an analysis of guidelines and systematic reviews", BMC Fam Pract, 14, pp.55~ (2013)
4. Freland L, "Inhibition of GSK3 by lithium, from single molecules to signaling networks", Front Mol Neurosci, 5, pp.14~ (2012)
5. Begić D, "EEG characteristics in depression, "negative"and"positive"schizophrena", Psychiatr Danub, 21, pp.579~584 (2009)
6. de la Torre C, "The delivery challenge in neurodegenerative disorders : the nanoparticles role in Alzheimer’s disease therapeutics and diagnostics", Pharmaceutics, 10, pp.190~ (2018)
7. Bienvenu OJ, "Psychiatric ‘diseases’versus behavioral disorders and degree of genetic influence", Psychol Med, 41, pp.33~40 (2011)
8. Li M, "Inflammatory biomarkers in depression : an opportunity for novel therapeutic interventions", Curr Psychiatry Rep, 13, pp.316~320 (2011)
9. Nestler EJ, "Epigenetic mechanisms of depression", JAMA Psychiatry, 71, pp.454~456 (2014)
10. Lakhan SE, "Biomarkers in psychiatry : drawbacks and potential for misuse", Int Arch Med, 3, pp.1~ (2010)
11. Krishnan V, "The molecular neurobiology of depression", Nature, 455, pp.894~902 (2008)
12. Alexander RC, "Clinical pharmacology in the development of new antidepressants : the challenges", Curr Opin Pharmacol, 14, pp.6~10 (2014)
13. Warden D, "The STAR*D Project results : a comprehensive review of findings", Curr Psychiatry Rep, 9, pp.449~459 (2007)
14. Anderson HD, "Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression : a retrospective US claims study", Clin Ther, 34, pp.113~123 (2012)
15. Sawada N, "Persistence and compliance to antidepressant treatment in patients with depression : a chart review", BMC Psychiatry, 9, pp.38~ (2009)
16. Monteggia LM, "Antidepressant actions of ketamine : from molecular mechanisms to clinical practice", Curr Opin Neurobiol, 30, pp.139~143 (2015)
17. Zarate CA, "Riluzole in psychiatry : a systematic review of the literature", Expert Opin Drug Metab Toxicol, 4, pp.1223~1234 (2008)
18. Casacalenda N, "Remission in major depressive disorder : a comparison of pharmacotherapy, psychotherapy, and control conditions", Am J Psychiatry, 159, pp.1354~1360 (2002)
19. Carpenter LL, "Transcranial magnetic stimulation(TMS)for major depression : a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice", Depress Anxiety, 29, pp.587~596 (2012)
20. Holtzheimer PE, "Deep brain stimulation for psychiatric disorders", Annu Rev Neurosci, 34, pp.289~307 (2011)
21. Brewer HB Jr, "Human plasma proapoA-I : isolation and amino-terminal sequence", Biochem Biophys Res Commun, 113, pp.626~632 (1983)
22. Suravajhala P, "Multi-omic data integration and analysis using systems genomics approaches : methods and applications in animal production, health and welfare", Genet Sel Evol, 48, pp.38~ (2016)
23. Menke A, "Gene expression: biomarker of antidepressant therapy?", Int Rev Psychiatry, 25, pp.579~591 (2013)
24. Peng B, "Functional metabolomics : from biomarker discovery to metabolome reprogramming", Protein Cell, 6, pp.628~637 (2015)
25. Aagaard K, "The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters", FASEB J, 27, pp.1012~1022 (2013)
26. Sonner Z, "The microfluidics of the eccrine sweat gland, including biomarker partitioning, transport, and biosensing implications", Biomicrofluidics, 9, pp.031301~ (2015)
27. Hendrickx H, "Metabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention", Neurobiol Aging, 26(Suppl 1), pp.1~5 (2005)
28. Tseng PT, "Increased levels of vascular endothelial growth factor in patients with major depressive disorder : a meta-analysis", Eur Neuropsychopharmacol, 25, pp.1622~1630 (2015)
29. Kaufman J, "The 5-HT1A receptor in major depressive disorder", Eur Neuropsychopharmacol, 26, pp.397~410 (2016)
30. Coplan JD, "A neurobiological hypothesis of treatment-resistant depression-mechanisms for selective serotonin reuptake inhibitor non-efficacy", Front Behav Neurosci, 8, pp.189~ (2014)
31. Hasler G, "Discovering endophenotypes for major depression", Neuropsychopharmacology, 29, pp.1765~1781 (2004)
32. Hiles SA, "Changes in interleukin-6, C-reactive protein and interleukin-10 in people with depression following antidepressant treatment: a meta-analysis", Brain Behav Immun, 24(Suppl 1), pp.S44~ (2010)
33. Molendijk ML, "Serum BDNF concentrations as peripheral manifestations of depression : evidence from a systematic review and meta-analyses on 179 associations(N=9484)", Mol Psychiatry, 19, pp.791~800 (2014)
34. Lin E, "Pharmacogenomics with antidepressants in the STAR*D study", Pharmacogenomics, 9, pp.935~946 (2008)
35. Strawbridge R, "Inflammation and clinical response to treatment in depression : a meta-analysis", Eur Neuropsychopharmacol, 25, pp.1532~1543 (2015)
36. Horowitz MA, "Neuroimmune and neuroendocrine abnormalities in depression : two sides of the same coin", Ann N Y Acad Sci, 1351, pp.68~79 (2015)
37. Juruena MF, "Overlap between atypical depression, seasonal affective disorder and chronic fatigue syndrome", Braz J Psychiatry, 29(Suppl 1), pp.S19~S26 (2007)
38. Beauchaine TP, "The role of biomarkers and endophenotypes in prevention and treatment of psychopathological disorders", Biomark Med, 3, pp.1~3 (2009)
39. LaBaer J, "So, you want to look for biomarkers(introduction to the special biomarkers issue)", J Proteome Res, 4, pp.1053~1059 (2005)
40. Pepe MS, "Insights into latent class analysis of diagnostic test performance", Biostatistics, 8, pp.474~484 (2007)
41. Le-Niculescu H, "Identifying blood biomarkers for mood disorders using convergent functional genomics", Mol Psychiatry, 14, pp.156~174 (2009)
42. Redei EE, "Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy", Transl Psychiatry, 4, pp.e442~ (2014)
43. Kambeitz JP, "The serotonin transporter in depression : meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression", J Affect Disord, 186, pp.358~366 (2015)
44. Joensuu M, "Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression", Psychiatry Clin Neurosci, 70, pp.34~41 (2016)
45. White KJ, "Drug addiction", pp.193~215 (2008), Springer
46. Björk K, "Regulation of serotonin receptor function in the nervous system by lipid rafts and adaptor proteins", Exp Cell Res, 316, pp.1351~1356 (2010)
47. Rivera-Baltanas T, "Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder", J Affect Disord, 137, pp.46~55 (2012)
48. Ersche KD, "Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment", Psychopharmacology(Berl), 214, pp.779~789 (2011)
49. López León S, "The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders : a meta-analysis", Biol Psychiatry, 57, pp.999~1003 (2005)
50. Burnashev N, "NMDA receptor subunit mutations in neurodevelopmental disorders", Curr Opin Pharmacol, 20, pp.73~82 (2015)
51. Gray AL, "Sex differences in glutamate receptor gene expression in major depression and suicide", Mol Psychiatry, 20, pp.1057~1068 (2015)
52. Petty F, "Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression", Biol Psychiatry, 37, pp.806~810 (1995)
53. Küçükibrahimoğlu E, "The change in plasma GABA, glutamine and glutamate levels in fluoxetine-or S-citalopramtreated female patients with major depression", Eur J Clin Pharmacol, 65, pp.571~577 (2009)
54. Devanand DP, "Effects of electroconvulsive therapy on plasma GABA", Convuls Ther, 11, pp.3~13 (1995)
55. Pehrson AL, "Altered -aminobutyric acid neurotransmission in major depressive disorder : a critical review of the supporting evidence and the influence of serotonergic antidepressants", Drug Des Devel Ther, 9, pp.603~624 (2015)
56. Bak LK, "The glutamate", GABA-glutamine cycle : aspects of transport, neurotransmitter homeostasis and ammonia transfer, 2006, pp.98, 641~653
57. Maddock RJ, "Brain imaging in behavioral neuroscience", pp.199~251 (2011), Springer
58. Dager SR, "Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders", Top Magn Reson Imaging, 19, pp.81~86 (2008)
59. Feyissa AM, "Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.70~75 (2009)
60. Dos Santos MCT, "miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease", Oncotarget, 9, pp.17455~17465 (2018)
61. Duman RS, "Neurobiology of stress, depression, and rapid acting antidepressants : remodeling synaptic connections", Depress Anxiety, 31, pp.291~296 (2014)
62. Dunlop BW, "Neuroimaging-based biomarkers for treatment selection in major depressive disorder", Dialogues Clin Neurosci, 16, pp.479~490 (2014)
63. Emamzadeh FN, "Alpha-synuclein structure, functions, and interactions", J Res Med Sci, 21, pp.29~ (2016)
64. Felger JC, "Inflammatory cytokines in depression : neurobiological mechanisms and therapeutic implications", Neuroscience, 246, pp.199~229 (2013)
65. Fernandes BS, "Serum brain-derived neurotrophic factor in bipolar and unipolar depression : a potential adjunctive tool for differential diagnosis", J Psychiatr Res, 43, pp.1200~1204 (2009)
66. Castrén E, "The role of BDNF and its receptors in depression and antidepressant drug action : reactivation of developmental plasticity", Dev Neurobiol, 70, pp.289~297 (2010)
67. Clark-Raymond A, "VEGF and depression : a comprehensive assessment of clinical data", J Psychiatr Res, 47, pp.1080~1087 (2013)
68. Malberg JE, "VGF, a new player in antidepressant action?", Sci Signal, 1, pp.pe19~ (2008)
69. Turner CA, "The fibroblast growth factor system and mood disorders", Biol Psychiatry, 59, pp.1128~1135 (2006)
70. Bernard R, "Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression", Mol Psychiatry, 16, pp.634~646 (2011)
71. Evans SJ, "Dysregulation of the fibroblast growth factor system in major depression", Proc Natl Acad Sci U S A, 101, pp.15506~15511 (2004)
72. Gaughran F, "Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder", Brain Res Bull, 70, pp.221~227 (2006)
73. Smith RS, "The macrophage theory of depression", Med Hypotheses, 35, pp.298~306 (1991)
74. Irwin MR, "Depressive disorders and immunity : 20 years of progress and discovery", Brain Behav Immun, 21, pp.374~383 (2007)
75. Maes M, "The new ‘5-HT’ hypothesis of depression : cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites(TRYCATs), both of which contribute to the onset of depression", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.702~721 (2011)
76. Miller AH, "Inflammation and its discontents : the role of cytokines in the pathophysiology of major depression", Biol Psychiatry, 65, pp.732~741 (2009)
77. Miller AH, "The role of inflammation in depression : from evolutionary imperative to modern treatment target", Nat Rev Immunol, 16, pp.22~34 (2016)
78. Raison CL, "Cytokines sing the blues : inflammation and the pathogenesis of depression", Trends Immunol, 27, pp.24~31 (2006)
79. Eyre HA, "A meta-analysis of chemokines in major depression", Prog Neuropsychopharmacol Biol Psychiatry, 68, pp.1~8 (2016)
80. Raison CL, "Inflammation and treatment resistance in major depression : the perfect storm", Psychiatr Times, 30 (2013)
81. Haapakoski R, "Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder", Brain Behav Immun, 49, pp.206~215 (2015)
82. Liu Y, "Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R)are elevated in patients with major depressive disorder: a meta-analysis and meta-regression", J Affect Disord, 139, pp.230~239 (2012)
83. Farooq RK, "Role of inflammatory cytokines in depression: focus on interleukin-1β", Biomed Rep, 6, pp.15~20 (2017)
84. Cattaneo A, "Absolute measurements of macrophage migration inhibitory factor and interleukin-1-β mRNA levels accurately predict treatment response in depressed patients", Int J Neuropsychopharmacol, 19, pp.pyw045~ (2016)
85. Baune BT, "Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging : the prospective Sydney Memory and Aging Study", Psychoneuroendocrinology, 37, pp.1521~1530 (2012)
86. Fornaro M, "Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds", J Affect Disord, 145, pp.300~307 (2013)
87. Hernández ME, "Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder", Eur Neuropsychopharmacol, 18, pp.917~924 (2008)
88. Hannestad J, "The effect of antidepressant medication treatment on serum levels of inflammatory cytokines : a meta-analysis", Neuropsychopharmacology, 36, pp.2452~2459 (2011)
89. Srikanthan K, "Systematic review of metabolic syndrome biomarkers : a panel for early detection, management, and risk stratification in the West Virginian population", Int J Med Sci, 13, pp.25~38 (2016)
90. Lu XY, "The leptin hypothesis of depression: a potential link between mood disorders and obesity?", Curr Opin Pharmacol, 7, pp.648~652 (2007)
91. Wittekind DA, "Ghrelin in psychiatric disorders-a review", Psychoneuroendocrinology, 52, pp.176~194 (2015)
92. Kan C, "A systematic review and meta-analysis of the association between depression and insulin resistance", Diabetes Care, 36, pp.480~489 (2013)
93. Liu X, "Plasma lipidomics reveals potential lipid markers of major depressive disorder", Anal Bioanal Chem, 408, pp.6497~6507 (2016)
94. Lustman PJ, "Depression and poor glycemic control : a meta-analytic review of the literature", Diabetes Care, 23, pp.934~942 (2000)
95. Maes M, "Evidence for an immune response in major depression : a review and hypothesis", Prog Neuropsychopharmacol Biol Psychiatry, 19, pp.11~38 (1995)
96. Pan A, "Bidirectional association between depression and metabolic syndrome : a systematic review and meta-analysis of epidemiological studies", Diabetes Care, 35, pp.1171~1180 (2012)
97. Carvalho AF, "Adipokines as emerging depression biomarkers : a systematic review and meta-analysis", J Psychiatr Res, 59, pp.28~37 (2014)
98. Lamers F, "Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression", Mol Psychiatry, 18, pp.692~699 (2013)
99. Zheng H, "Predictive diagnosis of major depression using NMR-based metabolomics and least-squares support vector machine", Clin Chim Acta, 464, pp.223~227 (2017)
100. Liu T, "A meta-analysis of oxidative stress markers in depression", PloS one, 10(10), pp.e0138904~ (2015)
101. Foulds PG, "Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease", FASEB J, 25, pp.4127~4137 (2011)
102. Fronczek R, "Hypocretin (orexin) loss in Parkinson’s disease", Brain, 130(Pt 6), pp.1577~1585 (2007)
103. Maes M, "Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis", chronic fatigue syndrome, 2009, pp.30, 715~722
104. Forlenza MJ, "Increased serum levels of 8-hydroxy-2’-deoxyguanosine in clinical depression", Psychosom Med, 68, pp.1~7 (2006)
105. Jorgensen A, "Systemic oxidatively generated DNA", RNA damage in clinical depression : associations to symptom severity and response to electroconvulsive therapy, 2013, pp.149, 355~362
106. Iida T, "Association of STAI and SDS scores with 8-hydroxydeoxyguanosine and serotonin levels in young women with depressive symptoms", J Neuropsychiatry Clin Neurosci, 23, pp.E10~ (2011)
107. Yi S, "Depressive symptoms and oxidative DNA damage in Japanese municipal employees", Psychiatry Res, 200, pp.318~322 (2012)
108. Chung CP, "Increased oxidative stress in patients with depression and its relationship to treatment", Psychiatry Res, 206, pp.213~216 (2013)
109. Gururajan A, "Molecular biomarkers of depression", Neurosci Biobehav Rev, 64, pp.101~133 (2016)
110. Parker KJ, "Neuroendocrine aspects of hypercortisolism in major depression", Horm Behav, 43, pp.60~66 (2003)
111. Stetler C, "Depression and hypothalamic-pituitary-adrenal activation : a quantitative summary of four decades of research", Psychosom Med, 73, pp.114~126 (2011)
112. Herane Vives A, "The relationship between cortisol, stress and psychiatric illness : New insights using hair analysis", J Psychiatr Res, 70, pp.38~49 (2015)
113. Fischer S, "Cortisol as a predictor of psychological therapy response in depressive disorders : systematic review and meta-analysis", Br J Psychiatry, 210, pp.105~109 (2017)
114. Anacker C, "The glucocorticoid receptor: pivot of depression and of antidepressant treatment?", Psychoneuroendocrinology, 36, pp.415~425 (2011)
115. Markopoulou K, "The ratio of cortisol", DHEA in treatment resistant depression, 2009, pp.34, 19~26
116. Marsden WN, "Synaptic plasticity in depression : molecular, cellular and functional correlates", Prog Neuropsychopharmacol Biol Psychiatry, 43, pp.168~184 (2013)
117. Duman RS, "Signaling pathways underlying the pathophysiology and treatment of depression : novel mechanisms for rapid-acting agents", Trends Neurosci, 35, pp.47~56 (2012)
118. Trivedi MH, "Establishing moderators and biosignatures of antidepressant response in clinical care(EMBARC) : rationale and design", J Psychiatr Res, 78, pp.11~23 (2016)

관련 논문AI추천